Abdulrahman Nasiri: D14 Bone Marrow Biopsy in AML Induction in the Era of Targeted Therapies
Abdulrahman Nasiri, Assistant Professor at Imam Muhammad ibn Saud Islamic University, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Proud to share our newly published review in Technology in Cancer Research and Treatment: ‘Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia Induction: The End of Story or Not Yet?
For years, the Day 14 bone marrow biopsy (D14 BMB) has guided AML treatment decisions, where less than five percent blasts strongly predicted complete remission following standard seven plus three induction.
However, as the treatment landscape shifts toward targeted therapies, we must re-evaluate this gold standard.
In our review, we explore:
- Evolving Kinetics: Novel agents like venetoclax induce slower blast clearance, meaning traditional D14 assessments may now be premature.
- Cellularity as a marker: Hypocellularity (less than twenty percent) remains a crucial, independent predictor of superior overall survival.
- The re-induction dilemma: Second-course therapy for persistent blasts increases remission rates but does not consistently translate to an overall survival benefit and carries significant morbidity risks.
- The shift to mrd: High-sensitivity Measurable Residual Disease (MRD) monitoring is increasingly becoming the standard for precise, long-term prognostic evaluation and risk stratification.
Our key takeaway: D14 BMB is not obsolete, but it must now be integrated into a risk-adapted framework that accounts for specific treatment modalities and MRD status.”
Title: Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia Induction: The End of Story or Not Yet?
Authors: Mostafa F. Mohammed Saleh, Abdulrahman Nasiri, Ahmed Abdrabou, Ali Alahmari, Syed O. Ahmed, Ayman Saad, Mahmoud Aljurf
Read Full Article on Sages Journals
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 15, 2026, 09:10Shall I Bleed Less with Age? Just 2 Weeks Until the Webinar – EHC
-
Apr 15, 2026, 08:51Moustafa Abdou: Sutimlimab is Transforming Outcomes in Cold Agglutinin Disease
-
Apr 15, 2026, 04:52Ulrich Pecks: Personalized Approaches to VTE Prevention in Pregnant Women with Inherited Thrombophilia
-
Apr 15, 2026, 04:06Brenda Pleasant: Insights from the HFA Symposium on Hemophilia Care
-
Apr 15, 2026, 03:43Lexy Halloran: Addressing Diagnostic Inequities in Women with Chronic Conditions
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS